Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine

Vaccine

Volumn 30, Issue 6, 2012, Pages 1023-1028

  An, So Jung ^a,b   Yoon, Yeon Kyung ^a   Kothari, Sudeep ^a   Kim, Deok Ryun ^a   Kim, Jeong Ah ^a   Kothari, Neha ^a   Lee, Eugene ^a   Park, Tai Hyun ^b   Carbis, Rodney ^a  

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Conjugate vaccine; Diphtheria toxoid; Hyporesponsiveness; Vi polysaccharide

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; DIPHTHERIA TOXOID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; TYPHOID DIPHTHERIA TOXOID CONJUGATE VACCINE; UNCLASSIFIED DRUG; VI CAPSULAR POLYSACCHARIDE;

ANTIBODY TITER; ARTICLE; DRUG CONJUGATION; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; DIPHTHERIA TOXOID; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED ICR; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE;

EID: 84856362045     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.046     Document Type: Article

References (40)

1. WHO. Weekly epidemiological record no. 6; 2008: 49-60.
2. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
3. Looney J.R., Steigbigal R.T. Role of the Vi antigen of Salmonella typhi in resistance to host defence in vitro. J Lab Clin Med 1986, 108:506-516.
4. Keitel W.A., Bond N.L., Zahradnik J., Crampton T.A., Robbins J.B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994, 12:195-199.
5. Robbins J.D., Robbins J.B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984, 150(3):436-449.
6. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269.
7. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166(5):1510-1524.
8. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysacchaide-protein conjugate vaccines. Infect Immun 1994, 62(10):4440-4444.
9. Kossaczka Z., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999, 67(11):5806-5810.
10. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992, 165(Suppl. 1):S49-S52.
11. Overbosch D., Peyron F., Picot N., Varichon J.P., Dumas R., Chambonneau L., et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant vaccine over 3 years. J Travel Med 2005, 12(6):319-326.
12. Peeters C.A.M., Tenbergen-Meekes A.J., Poolman J.T., Zegers B.J.M., Rijkers G.T. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 1992, 10(12):833-840.
13. An S.J., Yoon Y.K., Kothari S., Kothari N., Kim J.A., Lee E., et al. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 2011, 29(44):7618-7623.
14. WHO. WHO technical reports series, no. 840, 1994. Requirements for Vi polysaccharidetyphoid vaccine. WHO, Geneva, Switzerland; 1994.
15. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17(1):73-79.
16. Lebacq E. Comparative tolerability and immunogenicity of Typherix(TM) or Typhim(TM) in healthy adults: 0, 12-month and 0, 24-month administration. BioDrugs 2001, 15(Suppl. l):5-12.
17. MacLennan J., Obaro S., Deeks J., Williams D., Pais L., Carlone G., et al. Immune reponse to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999, 17:3086-3093.
18. Poolman J., Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011, 10(3):307-322.
19. Russell F.M., Carapetis J.R., Balloch A., Licciardi P.V., Jenney A.W.J., Tikoduadua L., et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010, 28:3341-3349.
20. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C-A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201(10):1570-1579.
21. Baker P.J. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect Immun 1990, 58(11):3465-3468.
22. Lundgren A., Suri-Payer E., Enarsson K., Svennerholm A-M., Lundin B.S. Helicobacter pylori-specific CD4+ CD25 high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003, 71(4):1755-1762.
23. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6(4):353-360.
24. + T cells with IL-10-mediated suppressive activity. Int Immunol 2001, 13(4):431-439.
25. Raffatellu M., Chessa D., Wilson R.P., Dusold R., Rubino S., Baumler A.J. The Vi capsular antigen of Salmonella enterica serovar Typhi reduces toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa. Infect Immun 2005, 73(6):3367-3374.
26. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Mengingococcal C polysaccharide vaccine induces immunological hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000, 181:761-764.
27. Borrow R., Goldblatt D., Andrews N., Richmond P., Southern J., Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001, 184:377-380.
28. Granoff D.M., Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26(8):716-722.
29. Mawas F., Feavers I.M., Corbel M.J. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococcal-CRM197 conjugate vaccines in a murine model. Vaccine 2001, 19:1159-1166.
30. Perlmutter R.M., Hansburg D., Briles D.E., Nicolotti R.A., Davie J.M. Subclass restriction of murine anti-carbohydrate antibodies. J Immunol 1978, 121(2):566-572.
31. Briles D.E., Claflin J.L., Schroer K., Mouse Forman C. IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 1981, 294:88-90.
32. Pulickal A.S., Gautam S., Clutterbuck E.A., Thorson S., Basynat B., Adhikari N., et al. Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol 2009, 16(10):1413-1419.
33. Lindow J.C., Fimlaid K.A., Bunn J.Y., Kirkpatrick B.D. Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi. Infect Immun 2011, 79(8):3188-3194.
34. Alonso M.J., Gupta R.K., Min C., Siber G., Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12(4):299-306.
35. Sales-Junior P.A., Guzman F., Vargas M.I., Sossai S., Patarroyo A.M., Gonzalez C.Z.L., et al. Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462. Vet Immunol Immunopathol 2005, 107:281-290.
36. Rodriguez M.E., van den Dobbelsteen G.P.J.M., Oomen L.A., de Weers O., van Buren L., Beurret M., et al. Immunogenicity of Streptococcus pneumoniae type 6 B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine 1998, 16(20):1941-1949.
37. Rondini S., Micoli F., Lanzilao L., Hale C., Saul A.J., Martin L.B. Evaluation of the immunogenicity and biological activity of Citrobacter freundii Vi CRM197 conjugates as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol. 2011, 18(3):460-468.
38. Szu S.C., Bystricky S., Hinojosa-Ahumada M., Egan W., Robbins J.B. Synthesis and some immunologic properties of an O-acetyl pectin poly (1-4)-α-D-GalpA-protein conjugate as a vaccine for typhoid fever. Infect Immun 1994, 62(12):5545-5549.
39. Ramachandran C., Wilk B.J., Hotchkiss A., Chau H., Eliaz I., Melnick S.J. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, natural killer (NK)-cells and induction of natural killer cell activity against K562 chronicmyeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med 2011, 11(59):1-9.
40. Inngjerdingen K.T., Patel T.R., Chen X., Kenne L., Allen S., Morris G.A., et al. Immunological and structural properties of a pectic polymer from Glinus oppositifolius. Glycobiology 2007, 17(12):1299-1310.